Print
18 October 2017
GMP News
In 2018, the Russian pharmaceutical manufacturers intend to increase their exports to Uzbekistan up to more than $60 million.
“According to our trade mission, the total volume of Uzbek imports of these products last year was $525 million, while the supplies from Russia amounted to about $50 million. Based on positive growth dynamics in this area over the recent years, Russian exports of medicinal products are projected to reach $56 million in 2017 and, in 2018, they will be worth more than $60 million,” said a source in the Russian trade mission.
These figures are expected to be achieved by implementing a number of joint projects. In H2 2016, the Ministry of Foreign Trade of Uzbekistan expressed interest in intensifying its contacts with the Russian manufacturers of medicines in order to increase the procurement of these products.
According to the source, this year, Uzbekistan was visited by representatives of 13 major Russian pharmaceutical companies from Moscow, Tatarstan, as well as Novosibirsk region, Sverdlovsk region, Ryazan region and other regions.
“Russian manufacturers held a presentation of their products at the international specialized exhibition in Tashkent. This led to agreements with their Uzbek partners on supplies of Russian goods. The meetings also demonstrated the interest in establishing joint ventures,” said the source.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.